Navigation Links
Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire

BASINGSTOKE, England, June 10 /PRNewswire-FirstCall/ -- The Board of Directors of Shire Limited (LSE: SHP)(NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that Graham Hetherington will join the Company as Chief Financial Officer and Executive Board Director on 1st July 2008.

Graham Hetherington has a broad range of experience in senior financial roles having most recently held positions as the Chief Financial Officer of Bacardi (2007) and Allied Domecq PLC (1999-2005). In his role at Allied Domecq he was a key member of the team that transformed the performance, shape and reputation of Allied Domecq, doubling shareholder value and overseeing a period of consistent earnings per share growth.

A Fellow of the Chartered Institute of Management Accountants (FCMA), Graham has valuable experience of leading finance functions for consumer brand driven organisations within the food and drink industry.

As previously announced, on June 18th 2008 Shire's current Chief Financial Officer, Angus Russell becomes Chief Executive Officer; he will also be acting Chief Financial Officer until 1st July, when Graham Hetherington takes up the position. On June 18th, Shire's current Chief Executive Officer Matthew Emmens becomes Chairman and Non-Executive Director, and Shire's current Chairman, Dr James Cavanaugh retires from the Shire Board.

Angus Russell, Shire current Chief Financial Officer commented:

"Graham brings to Shire a track record of delivering good financial results combined with extensive strategy, M&A and corporate development expertise in the rapidly changing food and drink industry."

Matthew Emmens, Shire current Chief Executive Officer added:

"We welcome Graham to the Shire Board. In addition to his contributions as the Company's Chief Financial Officer, he brings a wealth of financial experience as well as a new perspective from another highly competitive industry."

Graham Hetherington added:

"Shire stands out as a leader in its field because it has a differentiated model, a clear strategy and it is prepared to take calculated risks in the interest of consistently delivering growth and shareholder value. I'm pleased to be joining a company with such a track record of innovation and I'm looking forward to bringing my experience of strong consumer driven industries to the Shire organisation."

There are no details that are required to be disclosed under paragraph 9.6.13(2-6) of the UKLA Listing Rules.

Notes to Editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGFb3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

For further information please contact:

Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160

Eric Rojas (North America) +1-484-595-8252

Media Jessica Mann (Rest of the World) +44-1256-894-280

Matthew Cabrey (North America) +1-484-595-8248

Jessica Cotrone (North America) +1-617-613-4640

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
3. John Marshall and Kevin McGuinness Appointed to Ellex Board
4. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
5. David Mott Appointed Non Executive Director at Shire
6. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
7. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
8. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
9. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
10. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
11. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... a new closed system for isolating adipose-derived stem cells. The announcement starts a new ... adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess ...
(Date:11/30/2015)...  An interventional radiology technique shows promise for helping morbidly ... a study being presented today at the annual meeting of ... (RSNA). --> --> ... radiologists as a way to stop bleeding in emergency situations, ... of treating obesity is new. Mubin Syed , ...
(Date:11/30/2015)... ALBANY, N.Y. , Nov. 30, 2015 /PRNewswire-USNewswire/ ... led by assistant chemistry professor Jan Halámek, is ... level.   --> ...   --> ... researchers at UAlbany have discovered a straightforward concept ...
(Date:11/30/2015)... 30, 2015 Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... initiatives designed to create shareholder value. ... Spherix. "Based on published reports, the total addressable ... billion and Spherix will seek to secure fair ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
Breaking Biology News(10 mins):